These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 7898521

  • 1. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JM, van Oers RH, Haak HL.
    N Engl J Med; 1995 Apr 20; 332(16):1045-51. PubMed ID: 7898521
    [Abstract] [Full Text] [Related]

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 20; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 3. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

  • 4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL.
    N Engl J Med; 1995 Dec 07; 333(23):1540-5. PubMed ID: 7477169
    [Abstract] [Full Text] [Related]

  • 5. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL).
    Cancer; 2006 Jan 01; 106(1):136-45. PubMed ID: 16331635
    [Abstract] [Full Text] [Related]

  • 6. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    N Engl J Med; 1993 Apr 08; 328(14):1002-6. PubMed ID: 7680764
    [Abstract] [Full Text] [Related]

  • 7. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
    Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    N Engl J Med; 2005 Mar 24; 352(12):1197-205. PubMed ID: 15788496
    [Abstract] [Full Text] [Related]

  • 8. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
    Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, Sun Y.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 24; 31(6):469-73. PubMed ID: 19950562
    [Abstract] [Full Text] [Related]

  • 9. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
    Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB.
    N Engl J Med; 1997 Oct 30; 337(18):1259-66. PubMed ID: 9345074
    [Abstract] [Full Text] [Related]

  • 10. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
    Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang.
    N Engl J Med; 2004 Mar 25; 350(13):1287-95. PubMed ID: 15044639
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
    Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI.
    N Engl J Med; 1998 Jul 02; 339(1):21-6. PubMed ID: 9647875
    [Abstract] [Full Text] [Related]

  • 12. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
    Hausdorff J, Davis E, Long G, Hoppe R, van der Pas M, Lassman C, Kamel O, Jacobs C.
    Cancer J Sci Am; 1997 Jul 02; 3(5):303-11. PubMed ID: 9327155
    [Abstract] [Full Text] [Related]

  • 13. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G, Coser P, Congiu AM, Salvagno L, De Souza C, Sertoli MR, Olivieri A, Chisesi T, Rubagotti A, Truini M, Contu A, Porcellini A, Zambaldi G, Nati S, Marino G, Rizzoli V.
    Haematologica; 2000 Feb 02; 85(2):160-6. PubMed ID: 10681723
    [Abstract] [Full Text] [Related]

  • 14. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.
    Ai Zheng; 2006 Dec 02; 25(12):1543-9. PubMed ID: 17166383
    [Abstract] [Full Text] [Related]

  • 15. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
    Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R.
    N Engl J Med; 1996 Jul 11; 335(2):91-7. PubMed ID: 8649495
    [Abstract] [Full Text] [Related]

  • 16. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.
    Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M.
    N Engl J Med; 1987 Jun 11; 316(24):1493-8. PubMed ID: 3295541
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
    Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Löwenberg B, Rutten FF.
    Bone Marrow Transplant; 1995 Sep 11; 16(3):463-70. PubMed ID: 8535321
    [Abstract] [Full Text] [Related]

  • 18. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P, Cornillet P, Deconinck E, Tourani JM, Gardembas M, Delain M, Abgrall JF, Kootz C, Milpied N.
    Bone Marrow Transplant; 2000 Nov 11; 26(9):971-7. PubMed ID: 11100276
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 Nov 11; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
    Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, Berthou C, Ghandour C, Delwail V, Milpied N, Cassasus P, Celigny PS, Guyotat D, Lamy T, Desablens B, French GOELAMS Group.
    Haematologica; 2005 Jun 11; 90(6):802-9. PubMed ID: 15951293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.